Growth Metrics

Edwards Lifesciences (EW) Operating Leases (2019 - 2026)

Edwards Lifesciences has reported Operating Leases over the past 7 years, most recently at $107.1 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 35.74% year-over-year to $107.1 million; the TTM value through Dec 2025 reached $107.1 million, up 35.74%, while the annual FY2025 figure was $107.1 million, 35.74% up from the prior year.
  • Operating Leases for Q4 2025 was $107.1 million at Edwards Lifesciences, up from $75.3 million in the prior quarter.
  • Over five years, Operating Leases peaked at $107.1 million in Q4 2025 and troughed at $63.5 million in Q2 2022.
  • A 5-year average of $75.1 million and a median of $72.1 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: plummeted 31.37% in 2023 and later skyrocketed 35.74% in 2025.
  • Year by year, Operating Leases stood at $94.6 million in 2021, then increased by 0.42% to $95.0 million in 2022, then plummeted by 31.37% to $65.2 million in 2023, then rose by 21.01% to $78.9 million in 2024, then surged by 35.74% to $107.1 million in 2025.
  • Business Quant data shows Operating Leases for EW at $107.1 million in Q4 2025, $75.3 million in Q3 2025, and $78.7 million in Q2 2025.